Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Promisemed Hangzhou Meditech CoBJSE:920069 18 EBIT per Share is ¥-2.09 as of Jun. 2026. GuruFocus rates BJSE:920069 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 684 Medical Devices & Instruments companies, Promisemed Hangzhou Meditech Co ranks better than 63.16% on this metric.
Promisemed Hangzhou Meditech Co's EBIT per Share for the
three
months ended in Jun. 2026 was ¥0.65.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-2.09.
During the past 3 years, the average EBIT per Share Growth Rate was 18.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Promisemed Hangzhou Meditech Co's EBIT per Share or its related term are showing as below:
BJSE:920069'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 18.4 Med: 18.4 Max: 18.4
Current: 18.4
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Promisemed Hangzhou Meditech Co was 18.40% per year. The lowest was 18.40% per year. And the median was 18.40% per year.
BJSE:920069's 3-Year EBIT Growth Rate is ranked better than 63.16% of 684
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs BJSE:920069: 18.40
Promisemed Hangzhou Meditech Co (BJSE:920069) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Promisemed Hangzhou Meditech Co EBIT per Share Related Terms
Promisemed Hangzhou Meditech Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Promisemed Hangzhou Meditech Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-2.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Promisemed Hangzhou Meditech Co (BJSE:920069) has a EBIT per Share of ¥-2.09 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Promisemed Hangzhou Meditech Co and its competitors. According to the industry distribution chart, Promisemed Hangzhou Meditech Co ranks #252 out of 684 companies in the Medical Devices & Instruments industry, placing it in the top 36.8%.
Is Promisemed Hangzhou Meditech Co's EBIT per Share too high?
Promisemed Hangzhou Meditech Co's current EBIT per Share is ¥-2.09. Based on the distribution chart, Promisemed Hangzhou Meditech Co ranks #252 out of 684 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Promisemed Hangzhou Meditech Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Promisemed Hangzhou Meditech Co's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Promisemed Hangzhou Meditech Co ranks #252 out of 684 companies for EBIT per Share. This puts Promisemed Hangzhou Meditech Co in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Promisemed Hangzhou Meditech Co and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Promisemed Hangzhou Meditech Co's current EBIT per Share is ¥-2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Promisemed Hangzhou Meditech Co stock overvalued right now?
Promisemed Hangzhou Meditech Co (BJSE:920069) has a current EBIT per Share of ¥-2.09. The current EBIT per Share is ¥-2.09. Promisemed Hangzhou Meditech Co's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Promisemed Hangzhou Meditech Co (BJSE:920069), the current EBIT per Share is ¥-2.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Promisemed Hangzhou Meditech Co Ltd is engaged in the Research, development, production and sales of diabetes care, universal drug delivery and infusion, and minimally invasive interventional medical devices.
18GF Score
Get the complete analysis for BJSE:920069
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920069 has been successfully added to your 
